June 6, 2017
Novo Nordisk to sell its haemophilia B drug in EU
European Commission has granted marketing authorisation for Novo Nordisk’s Refixia for the treatment of adolescents and adults with haemophilia B.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
June 6, 2017
WHO ranks antibiotics depending on seriousness of condition
World Health Organization (WHO) has updated Essential Medicines List with new advice on which antibiotics to use for common infections and which to preserve for the most serious circumstances is among the additions to the WHO Model list of essential medicines for 2017.
June 6, 2017
BMS and Novartis join forces to fight cancer
Bristol-Myers Squibb and Novartis have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen in combination with Mekinist (trametinib), as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).
June 6, 2017
CTI BioPharma prices underwritten public offering of $45M of convertible preferred stock
CTI BioPharma has announced the pricing of an underwritten public offering of 22,500 shares of its Series N-3 Preferred Stock, offered at a price to the public of $2,000 per share of Series N-3 Preferred Stock (the “Offering”).
June 6, 2017
FDA OK’s Alkermes’s schizophrenia drug
The U.S. Food and Drug Administration (FDA) has approved Alkermes’s two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.
June 6, 2017
European Commission approves Novartis’s leukemia drug
European Commission (EC) has approved the inclusion of Treatment-free Remission (TFR) data in the Novartis’s Tasigna (nilotinib) Summary of Product Characteristics (SmPC).
June 5, 2017
BMS and QIAGEN join forces to study cancer using NGS technology
Bristol-Myers Squibb and QIAGEN have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as predictive or prognostic tools for use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies in cancer treatment.
June 2, 2017
Novartis’s metastatic breast cancer drug improves PFS, updated results show
Novartis has updated findings from the Phase III MONALEESA-2 study that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
June 1, 2017
Novartis CEO sees no need for big takeover
Novartis does not need a big acquisition to kick-start growth, Chief Executive Joe Jimenez told investors on Wednesday, playing down suggestions he could use proceeds from a slew of asset sales for a significant takeover.
June 1, 2017
Vertex has good news for 500 Irish patients with cystic fibrosis
Vertex Pharmaceuticals Incorporated has reached an agreement with the Health Service Executive (HSE) in the Republic of Ireland to fund Orkambi (lumacaftor/ivacaftor).